CN1209115C - Active extracted composition of teasel root and notoginseng and use in medicine - Google Patents
Active extracted composition of teasel root and notoginseng and use in medicine Download PDFInfo
- Publication number
- CN1209115C CN1209115C CN 03112869 CN03112869A CN1209115C CN 1209115 C CN1209115 C CN 1209115C CN 03112869 CN03112869 CN 03112869 CN 03112869 A CN03112869 A CN 03112869A CN 1209115 C CN1209115 C CN 1209115C
- Authority
- CN
- China
- Prior art keywords
- medicine
- notoginseng
- radix notoginseng
- radix
- teasel root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 47
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 241000123589 Dipsacus Species 0.000 title abstract 5
- 229930182490 saponin Natural products 0.000 claims abstract description 30
- 150000007949 saponins Chemical class 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims description 24
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 12
- 230000001009 osteoporotic effect Effects 0.000 claims description 5
- 235000017709 saponins Nutrition 0.000 abstract description 28
- 206010017076 Fracture Diseases 0.000 abstract description 22
- 208000010392 Bone Fractures Diseases 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 14
- 208000001132 Osteoporosis Diseases 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 description 22
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 5
- 230000037182 bone density Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 210000002303 tibia Anatomy 0.000 description 4
- -1 3 times Substances 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 2
- 206010061363 Skeletal injury Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035616 enchondral ossification Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 241001419719 Anisodus carniolicoides Species 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000123586 Dipsacaceae Species 0.000 description 1
- 241001050741 Dipsacus asperoides Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 208000005214 Poroma Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
- 201000001013 eccrine acrospiroma Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- HQFCOGRKGVGYBB-UHFFFAOYSA-N ethanol;nitric acid Chemical compound CCO.O[N+]([O-])=O HQFCOGRKGVGYBB-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 239000009705 sanhuang Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an active extracted composition of teasel root and notoginseng and the application to the preparation of the medicine for curing fracture and osteoporosis, which is developed by utilizing a modern medicine theory on the basis of a conventional traditional Chinese medicine theory and has the advantages of simple prescription, specific effective component, outstanding curative effect and controllable quality. The active extracted composition of teasel root and notoginseng is composed of teasel root total saponins and notoginseng total saponins with the weight ratio of 1: 0.2 to 15, and the optimum weight ratio of the teasel root total saponins to the notoginseng total saponins is 1: 0.5 to 5.
Description
Technical field:
The present invention relates to the active extract composition of a kind of Radix Dipsaci and Radix Notoginseng and pharmaceutically using.This extraction compositions is respectively on-off total saponin as well as and Radix Notoginseng total arasaponins.Said composition can be used for making treatment fracture and osteoporotic medicine.
Background technology:
Fracture is common damage, and old people and postmenopausal women be because the rapid minimizing of whole body bone amount, and the fragility of bone increases after the osteoporosis, and microtrauma can be fractured.The American scholar report postmenopausal women about 1/3～1/2 fracture because of osteoporosis, and the annual fracture that takes place is about 1,300,000 people, annual therefore expensive about 10,000,000,000 dollars.The fracture incidence rate that the Shanghai scholar reports 10429 old peoples more than 60 years old is 15.6%.And because healing is poor, complication is many, usually threat to life behind the senile fracture.Doctor trained in Western medicine does not still have obvious catagmatic medicine at present to the treatment of fractures reduction of the fracture commonly used and fracture fixation method.
Aspect bone healing, China's tradition Chinese medicine often adopts blood circulation promoting and blood stasis dispelling, and reducing swelling and alleviating pain is mended the bone bone strengthening, and the method for treatment of promoting tissue regeneration by removing blood stasis has original benefit, for doctor trained in Western medicine institute can not reach.Tradition Chinese patent medicine such as notoginseng injury tablet, powder for fracture and trauma, YUNNAN BAIYAO, Anisodus carniolicoides C.Y.Wu et C.Chen, pill for traumatic injuries, Yuzhen San, SANHUANG Apis cerana Fabricius ball, tiger bone-papaya wine, damage medicated wine etc., owing to comprise tens flavors at least in these medicaments, at most tens the flavor medical materials, the quality standard that most of neither ones are controlled, in a large amount of clinical case treatments, be difficult to obtain satisfied curative effect, also can partly leave over bone injury sequela sometimes.Therefore on the basis of traditional Chinese medicine theory, utilization modern medicine theory is developed a kind of determined curative effect, and quality controllable orthopedics department medication is significant.
Osteoporosis be a kind of with the bone amount reduce, the osseous tissue microstructure is unusual and fracture risk increases to a class disease of feature, is common in particularly postmenopausal women of old people, its sickness rate height, harm is big.At present, the treatment doctor trained in Western medicine of this disease mainly with estrogen, calcium preparation, calcitonin, Diphosphonate and fluoride preparation etc., because existing, these medicines is cost an arm and a leg reason such as the life-time service medication is dissatisfied, and side effect is big.Therefore, people turn to sight Chinese medicine in the excavation and research aspect the treatment osteoporosis gradually.
Summary of the invention:
The objective of the invention is to overcome the deficiency of above-mentioned Western medicine prior art and existing Chinese patent medicine, on the basis of traditional Chinese medicine theory, utilization modern medicine theory, developing a kind of prescription simplifies, effective ingredient is clear and definite, determined curative effect, quality controllable Radix Dipsaci and the active extract composition of Radix Notoginseng.
Another object of the present invention is to said composition and can be used for making the application for the treatment of in fracture and the osteoporotic medicine.
Purpose of the present invention can reach by following measure:
The present invention is made up of the activity extract of Radix Dipsaci and Radix Notoginseng.Exactly be made up of on-off total saponin as well as and Radix Notoginseng total arasaponins, its weight ratio is 1: 0.2～15, and its optimum weight ratio is 1: 0.5～5.
Radix Dipsaci is a Dipsacaceae plant Radix Dipsaci Dipsacus asperoides C.Y.Cheng et T.M.Ai dry root.The tool invigorating the liver and kidney, bone and muscle strengthening, continuous folding is hindered, and ends the effect of metrorrhagia.Be used for soreness of the waist and knees, rheumatic arthralgia, diseases such as injury from falling down.The total Saponin of Radix Dipsaci is the active component that Radix Dipsaci promotes bone injury healing effect.Radix Notoginseng is the dry root of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen.The hemostasis of tool dissipating blood stasis, the effect of subduing swelling and relieving pain.Be used for spitting of blood, spit blood epistaxis, traumatic hemorrhage, diseases such as tumbling and swelling.Radix Notoginseng is the incised wound key medicine, is commonly used for the monarch drug of injury from falling down medicine, and single, and compound recipe all can be used as medicine, and as Radix Notoginseng Tabellae, Radix Notoginseng total glucosides tablet, notoginseng injury tablet, pill for traumatic injuries etc. all are monarch drug with the Radix Notoginseng.Its effective ingredient is a Radix Notoginseng total arasaponins.As seen by above-mentioned, Radix Dipsaci is longer than invigorating the kidney and strengthening the bones, and Radix Notoginseng is longer than the dissipating blood stasis for subsidence of swelling analgesic therapy, and two medicines share, particularly two the effective elements of the medicines share, and can reach blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, the effect of mending the bone bone strengthening, and this prescription is simplified, and effective ingredient is clear and definite, the deficiency of complementary single medicinal material.
The present invention has the bone of benefit bone strengthening, and the effect of continuous folding wound can be used for making treatment fracture and osteoporotic medicine.
Pharmacodynamic study of the present invention is as follows:
1. to the effect of rat test treatment of fractures
24 of SD rats, male and female half and half are divided into 3 groups at random by the sex body weight, 8 every group.Be respectively blank group, positive drug control group (JIEGU QILI PIAN group), this medicine group.Cause wide 2mm every rat tibia, the damaged model of bone of dark 1mm.Rose in the 2nd day, every day gastric infusion, wherein, positive control pharmaceutical quantities 0.65g/kg, this medicine group 0.46g/kg, continuous 15 days, 24 hours sacrificed by decapitation were separated each tibia after the last administration, surveyed its former damaged place bone girth; And put into 4% formalin fixing after, the nitric acid ethanol decalcification with 7% is after 24 hours, in the rip cutting embedding of the damaged place of bone, the analysis of cutting into slices the results are shown in down:
The girth at the damaged place of tibia of each treated animal of table 1. (n=6, X ± SD, mm)
| Group | Dosage (g/kg) | Girth |
| Blank | 8.78±0.41 | |
| Positive control | 0.65 | 10.50±1.59 |
| This medicine group | 0.46 | 19.13±1.89* |
Annotate: * P＜0.01, with blank group ratio.
The pathology section examination result at the damaged place of tibia of each treated animal of table 2.
| Group | Blank | Positive control | This medicine group |
| Example number naked eyes indenture is observed fusiformis swelling poroma formation enchondral ossification mirror bone trabecula abundance area of new bone line parallel bone trabecula and is examined back shape trabecular bone mother cell interfibrillar substance | 5 1/5 0 + - + + + - + + | 5 3/5 0 + - ++ - + - + + | 6 4/6 2/6 +++ ++ ++ +++ - ++ +++ +++ |
As can be seen from the results, this medicine can make the callus at the damaged place of bone obviously thicken, and the bone girth increases, and illustrates that this medicine can promote the fracture osteogenesis; Further confirm the effect of this medicine from the tissue slice microscopy, it makes fracture present active bone skeletonization or enchondral ossification, and the osteoblast hypertrophy is very active, fibrosis callus bulge occurs, and this and blank and positive drug group relatively have tangible difference.
2. to the effect of rabbit experiment treatment of fractures
10 of rabbit are divided into 2 groups at random, are respectively blank group, this medicine group.1/3 place causes the standard fracture mouth that 3mm is wide, 2mm is dark under every rabbit radius.The hands second day after operation rises, CMC-Na 2ml/kg and this medicine 60mg/2ml/1kg of difference ig 0.5%, continuous 25 days.Put to death rabbit, separate each radius, survey the girth of its fracture, and measure its bone density, the results are shown in following table with the DEXA borne densitometers.
The girth at the damaged place of radius of two groups of rabbit of table 3. (n=5, X ± SD, mm)
| Group | Dosage (mg/kg) | Girth |
| This medicine of blank group | 60 | 18.0±1.1 22.1±0.8 * |
Annotate: * P＜0.01, with blank group ratio.
Bone density value (n=5, X ± SD, the g/cm at the damaged place of radius of two groups of rabbit of table 4.
2)
| Group | Dosage (mg/kg) | Girth |
| This medicine of blank group | 60 | 0.295±0.042 0.412±0.034 * |
Annotate: * P＜0.01, with blank group ratio.
The result shows that the girth at the damaged place of radius of this medicine group illustrates that apparently higher than matched group it can promote the formation of fracture callus; Simultaneously, apparently higher than matched group, further illustrate the effect of the short knitting of medicine as an objective indicator bone density value that reflects union of fracture.In addition, it is to cause osteoporotic direct and The key factor that the bone amount reduces, and this medicine is bone density improving significantly, illustrates that this medicine also has function of resisting osteoporosis.
The specific embodiment:
Embodiment 1:
The preparation of on-off total saponin as well as: get Radix Dipsaci decoction pieces 600g, add 80% ethanol of 7 times of medical material weight, reflux, extract, 3 times, extract 2 respectively, 2,1 hour, filter, merge extractive liquid, reclaims ethanol to there not being alcohol, and be condensed into the aqueous solution of 1g crude drug/ml, through ethyl acetate, water-saturated n-butanol respectively extracts 3 times, and the reclaim under reduced pressure n-butyl alcohol is done near, adds the small amount of methanol dissolving, in methanol solution, add ethyl acetate again, separate out precipitation, filter, get precipitation, dry, pulverize, cross 55 mesh sieves, promptly get the yellow on-off total saponin as well as finished product of ancestor, weight is 29.5g, and on-off total saponin as well as content is 52.2%.
Embodiment 2:
The preparation of Radix Notoginseng total arasaponins: get pseudo-ginseng and be ground into coarse powder 300g, add 70% ethanol of 8 times of medical material weight, reflux, extract, 3 times, extract 2 respectively, 2,1 hour, filter, merge extractive liquid, reclaims ethanol to there not being alcohol, and be condensed into the aqueous solution of 1g crude drug/ml, through ethyl acetate, water-saturated n-butanol respectively extracts 3 times, and the reclaim under reduced pressure n-butyl alcohol is done near, adds the small amount of methanol dissolving, in methanol solution, add ethyl acetate again, separate out precipitation, filter, get precipitation, dry, pulverize, cross 55 mesh sieves, promptly get the yellow Radix Notoginseng total arasaponins finished product of shallow ancestor, weight is 8.5g, and content of the total saponins in radix notoginseng is 54.5%.
Embodiment 3:
Close decoction and prepare on-off total saponin as well as and Radix Notoginseng total arasaponins: get Radix Dipsaci decoction pieces 600g and pseudo-ginseng coarse powder 300g and mix, 80% ethanol that adds 8 times of medical material weight, reflux, extract, 3 times, extract 2 respectively, 2,1 hour, filter, merge extractive liquid, reclaims ethanol to there not being alcohol, and be condensed into the aqueous solution of 1g crude drug/ml, through ethyl acetate, water-saturated n-butanol respectively extracts 3 times, and the reclaim under reduced pressure n-butyl alcohol is done near, adds the small amount of methanol dissolving, in methanol solution, add ethyl acetate again, separate out precipitation, filter, get precipitation, dry, pulverize, cross 55 mesh sieves, promptly get the mixture finished product of khaki on-off total saponin as well as and Radix Notoginseng total arasaponins, weight is 39.3g, and on-off total saponin as well as and content of the total saponins in radix notoginseng summation are 50.5%.
Embodiment 4:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 20g and Radix Notoginseng total arasaponins finished product 4g, add starch 76g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 5:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 20g and Radix Notoginseng total arasaponins finished product 10g, add starch 70g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 6:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 10g and Radix Notoginseng total arasaponins finished product 10g, add starch 80g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 7:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 4g and Radix Notoginseng total arasaponins finished product 20g, add starch 76g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 8:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 2g and Radix Notoginseng total arasaponins finished product 20g, add starch 78g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 9:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: with on-off total saponin as well as finished product 2g and Radix Notoginseng total arasaponins finished product 30g, add starch 68g, mix homogeneously, the back filled capsules or make tablet of granulating.
Embodiment 10:
The preparation of the total saponin extracts of Radix Dipsaci and Radix Notoginseng: press embodiment 3 prepared Radix Dipsacis and Radix Notoginseng total arasaponins finished product 25g, add starch 75g, mix homogeneously, the back filled capsules or make tablet of granulating.
Claims (4)
1. the active extract composition of Radix Dipsaci and Radix Notoginseng is characterized in that said composition is made up of on-off total saponin as well as and Radix Notoginseng total arasaponins, and its weight ratio is 1: 0.2～15.
2. the active extract composition of Radix Dipsaci according to claim 1 and Radix Notoginseng is characterized in that the optimum weight ratio of on-off total saponin as well as and Radix Notoginseng total arasaponins is 1: 0.5～5 in the said composition.
3. the application of the active extract composition of claim 1 or 2 described Radix Dipsacis and Radix Notoginseng in the medicine of preparation treatment fracture.
4. the application of the active extract composition of claim 1 or 2 described Radix Dipsacis and Radix Notoginseng in the osteoporotic medicine of preparation treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112869 CN1209115C (en) | 2003-02-24 | 2003-02-24 | Active extracted composition of teasel root and notoginseng and use in medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112869 CN1209115C (en) | 2003-02-24 | 2003-02-24 | Active extracted composition of teasel root and notoginseng and use in medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1433767A CN1433767A (en) | 2003-08-06 |
| CN1209115C true CN1209115C (en) | 2005-07-06 |
Family
ID=27634163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03112869 Expired - Fee Related CN1209115C (en) | 2003-02-24 | 2003-02-24 | Active extracted composition of teasel root and notoginseng and use in medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1209115C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100605116B1 (en) * | 2004-07-05 | 2006-07-31 | 주식회사 오스코텍 | Composition for preventing and treating periodontal disease containing Samchil-Geun extract as an active ingredient |
| CN102631420B (en) * | 2012-04-24 | 2013-09-18 | 吉林大学珠海学院 | Traditional Chinese medicine preparation capable of easing pain, diminishing inflammation and treating osteoporosis |
| CN107006765A (en) * | 2017-05-05 | 2017-08-04 | 泰山医学院 | A kind of preparation method for helping to move the Dietotherapy health congee of caused fracture and injury and the fast quick-recovery of soft tissue bruise |
| CN107982466A (en) * | 2017-12-27 | 2018-05-04 | 高永腾 | A kind of Chinese medicine composition for treating fracture and preparation method thereof |
-
2003
- 2003-02-24 CN CN 03112869 patent/CN1209115C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1433767A (en) | 2003-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN104547585B (en) | The external medicine composition and preparation for the treatment of swelling and pain, edge of a knife wound and exanthemv | |
| CN1209115C (en) | Active extracted composition of teasel root and notoginseng and use in medicine | |
| CN1259955C (en) | Chinese medicine preparation for treating climacteric metancholia of women | |
| CN101485722B (en) | Rhizoma drynariae and salvia miltiorrhiza medicinal composition and application thereof | |
| CN116159098B (en) | Composition for preventing and treating degenerative osteoarthritis lesions | |
| CN114209764B (en) | Pharmaceutical composition, preparation and application for treating fracture | |
| CN107773679A (en) | A kind of composition and its preparation technology for aiding in reducing blood lipid, aiding in thrombus | |
| CN1270740C (en) | Ready prepared Chinese medicine for treating angeitis and preparation process | |
| CN100409892C (en) | Externally applied medicament for treating hyperplasia of mammary glands and preparation method thereof | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| CN1931300A (en) | Externally applied medicine for treating women's dysmenorrhea | |
| CN117959361B (en) | Pharmaceutical composition for strengthening tendons and bones and preparation method thereof | |
| CN100428952C (en) | Medicine for treating climacteric syndrome and preparation method thereof | |
| CN1879748A (en) | A group of compound Chinese medicinal oral preparation for treating osteoporosis and preparation method thererof | |
| CN116870076B (en) | Anti-inflammatory analgesic traditional Chinese medicine composition and preparation method and application thereof | |
| CN115737729B (en) | An ethnic medicinal preparation for treating osteoporosis and its preparation method | |
| CN1092968C (en) | Pharmaceuticals for treating outer skin blood vessel diease in cold seasons | |
| CN1205989C (en) | Medicine composition for treating ischemic necrosis of femur head and preparing process thereof | |
| CN1528415A (en) | Capsule for treating cervical spondylosis and hyperplastic arthritis and preparing process thereof | |
| CN109718280B (en) | A Chinese medicinal composition for treating female climacteric syndrome, and its preparation method | |
| CN100459981C (en) | A kind of pharmaceutical composition for treating bruises | |
| CN1814122A (en) | Medicine for treating osteoporosis and preparing method | |
| CN1259940C (en) | Medicinal composition for treatnig bone fracture | |
| CN1493325A (en) | Chinese medicine for treating osteoporosis and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050706 |